How Much Does Biktarvy Cost Per Month?

The price of a single 30-day supply of Biktarvy varies more by your insurance situation than by anything else. Here is what patients in each coverage category typically pay out of pocket.

Biktarvy pricing confuses people because the headline number — the list price — almost never matches what a real patient pays. The questions below address what people actually search for, answered plainly.

• 1
  How much does Biktarvy cost per month in the USA? List price: $4,216/month · Commercially insured patients with copay card: $0–$5/month · Medicare/Medicaid patients: often $0–$10/month with assistance

  As of January 2026, the wholesale list price for Biktarvy is $4,216 for a 30-day supply. That figure is published by the manufacturer and reflects what’s billed before insurance, rebates, or assistance programs are applied — it is essentially never the amount a patient pays at the counter. Patients with commercial insurance through an employer or the ACA marketplace typically pay between $0 and $5 a month once they enroll in the manufacturer’s copay savings card. Patients on Medicare or Medicaid pay differently — government insurance rules block the manufacturer’s copay card, but nonprofit foundation grants and the new Medicare out-of-pocket cap often bring monthly costs down to a similarly small number. The single most important step for anyone facing a high quote is to call and ask about assistance before assuming the list price applies to them.
• 2
  Is there a generic version of Biktarvy? No — and none is expected before November 2036 at the earliest · Biktarvy remains brand-only nationwide · Patent protection runs through at least 2031–2033

  There is currently no FDA-approved generic version of Biktarvy anywhere in the United States, and the earliest projected date for one to reach the market is November 2036. The combination of three active ingredients in a single tablet is protected by a series of patents, the last of which doesn’t expire until the early 2030s, with regulatory exclusivity extending the brand-only period further. Several drug companies have filed legal challenges attempting to bring a generic to market sooner, but as of 2026 none has been approved. This is the core reason the list price stays elevated — there is no lower-cost competing product to push pricing down the way generics typically do for older medications. For patients focused on minimizing cost today rather than waiting years for a generic, the assistance programs described throughout this guide are the realistic path to an affordable monthly payment.
• 3
  What does Biktarvy cost with Medicare? Without help: typically $50–$200/month depending on plan and time of year · With Medicare Extra Help: $0–$10/month · New 2026 rule: all Part D out-of-pocket drug spending caps at $2,000 per year

  Medicare Part D plans cover Biktarvy, but every plan structures its costs differently depending on the drug’s tier on that plan’s formulary. A significant change took full effect in 2026: all Medicare Part D and Medicare Advantage drug plans now cap a beneficiary’s total annual out-of-pocket prescription spending at $2,000. Once you hit that cap — which can happen quickly with a drug priced like Biktarvy — your plan covers 100% of covered prescription costs for the remainder of the calendar year. Before reaching the cap, you’ll typically pay a deductible (up to $615 in 2026, though many plans set it lower) followed by a copay or coinsurance percentage. Medicare beneficiaries with limited income may qualify for Extra Help (also called the Low-Income Subsidy), which reduces copays to roughly $0 to $10 per prescription — apply through the Social Security Administration. Because Gilead’s manufacturer copay card cannot legally be used with Medicare, beneficiaries facing a gap should instead contact nonprofit copay foundations, several of which specifically fund HIV treatment costs for Medicare patients.
• 4
  Is Biktarvy free for people without insurance? Potentially yes — income-qualifying uninsured patients can receive it at no cost · Apply through the manufacturer’s patient assistance program · State ADAP programs offer a parallel free option

  Uninsured patients are not automatically stuck paying the $3,800–$5,000 cash price. Gilead, the company that makes Biktarvy, operates a Patient Assistance Program that provides the medication free of charge to qualifying uninsured or underinsured patients based on income and residency. There’s no requirement to demonstrate extreme financial hardship — many patients with modest incomes qualify. Separately, every state operates an AIDS Drug Assistance Program (ADAP) through the federally funded Ryan White HIV/AIDS Program, which covers HIV medications including Biktarvy for eligible low-income residents regardless of insurance status. Income limits and the exact application process vary by state, so the right first call is your local Ryan White clinic or your state health department’s ADAP coordinator. Between these two avenues, the overwhelming majority of people who cannot otherwise afford Biktarvy have a realistic path to getting it at no cost — the challenge is usually awareness of the programs, not eligibility.
• 5
  How does the Biktarvy copay card work? Up to $7,200 per year in assistance · No monthly limit on the amount it can cover · Only available to patients with commercial (private/employer) insurance · Cannot be combined with Medicare, Medicaid, VA, or Tricare

  The Gilead Advancing Access copay savings card is a manufacturer-funded discount card, not an insurance plan, that reduces what commercially insured patients owe at the pharmacy. It can provide up to $7,200 in cost-sharing assistance per calendar year, and importantly there is no monthly cap on how much of that total can be used in a single fill — useful for patients who must meet a large deductible early in the year. Most patients who use it report paying between $0 and $5 a month. Enrollment doesn’t require proving financial hardship; most people with qualifying commercial insurance are accepted. The major catch is eligibility: it explicitly cannot be used by anyone enrolled in Medicare, Medicaid, Medigap, VA, Department of Defense, or Tricare coverage, due to federal regulations governing manufacturer discounts and government health programs. Patients on those programs need to use the separate foundation and state assistance routes described elsewhere in this guide.
• 6
  Why is Biktarvy so expensive? No generic competition exists yet · Patent protection runs through at least the early 2030s · It’s a complex three-drug combination requiring years of R&D and trials · Pricing reflects single-manufacturer exclusivity, not unusual profiteering for the drug category

  Biktarvy’s price reflects a combination of factors common to brand-name specialty medications still under patent. As a single-tablet regimen combining three separate antiretroviral compounds, it required extensive research, clinical trials, and manufacturing investment, and as the sole supplier with no generic competitor, Gilead sets pricing without the downward pressure that competition typically creates. This pattern is consistent across most newer HIV treatments — older HIV drugs that have lost patent protection and gained generic competitors, such as some emtricitabine/tenofovir combinations, cost dramatically less. The expectation, based on typical patent-cliff pricing behavior, is that once a generic Biktarvy becomes available no earlier than 2036, prices for the category will fall sharply, similar to the 80–95% price drops seen historically within a year or two of generic entry for other major drug classes.
• 7
  Does Medicaid cover Biktarvy? Yes — covered in all 50 state Medicaid formularies · Typical out-of-pocket cost: $0 to $3 per month · No separate enrollment needed beyond standard Medicaid coverage

  Biktarvy appears on the Medicaid formulary in every state, and Medicaid is in fact the single largest payer for HIV treatment nationwide. Most Medicaid beneficiaries pay nothing or a small nominal copay, typically in the range of $0 to $3 per prescription, well below what commercial or even Medicare patients without assistance might owe. Because coverage rules and any applicable copay amounts are set at the state level, exact details vary — some states waive cost-sharing for HIV medications entirely as a public health policy matter. If you’re uninsured and have a low income, it’s worth checking Medicaid eligibility in your state before assuming you don’t qualify; expansion states cover adults earning up to roughly 138% of the federal poverty level, which works out to about $20,800 a year for a single adult in 2026. Eligibility can be checked free through Medicaid.gov or your state’s Medicaid office.
• 8
  What if my Biktarvy prescription is denied or hard to fill? Biktarvy is not on the FDA’s national drug shortage list — supply nationally is adequate · Local pharmacy stock-outs are a distribution issue, not a true shortage · For coverage denials, Gilead offers free help with prior authorization and appeals

  Two separate issues sometimes get confused: insurance coverage denial and physical drug shortage. As of early 2026, Biktarvy is not listed on the FDA’s national drug shortage database, meaning the manufacturer is producing and distributing adequate national supply. If your specific pharmacy says it’s out of stock, that typically reflects a local distribution gap rather than a true nationwide shortage — calling a few other pharmacies in your area, or asking your prescriber about a specialty pharmacy with more reliable inventory, usually resolves it. If instead your insurance company has denied coverage or is requiring prior authorization or step therapy before approving Biktarvy, Gilead’s patient support team offers free assistance navigating the appeals process alongside your prescriber’s office. About 98% of commercially insured patients can access Biktarvy without facing prior authorization hurdles, according to manufacturer data, so a denial is relatively uncommon and often successfully overturned on appeal.

Use the buttons below to find HIV care clinics, pharmacies, and assistance offices near you. Always confirm current pricing and program eligibility directly with the organization before relying on it.